Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A 5-year follow-up study confirms that while polyacrylamide hydrogel (PAHG) injection is safer, it fails to meet noninferiority criteria compared to tension-free vaginal tape (TVT) for patient satisfaction and long-term efficacy in stress u
Higher adherence to the Life’s Essential 8 cardiovascular health score is positively linked to improved sperm quality parameters, including count and motility, in reproductive-aged men.
A prospective multicenter study confirms that the proudP mobile app provides reliable, acoustic-based uroflowmetry measurements for BPH patients undergoing TURP, showing high correlation with clinical standards and significant patient satis
A secondary analysis of a randomized clinical trial finds that Hatha yoga does not provide superior sleep benefits compared to general physical conditioning in women with urinary incontinence, despite the strong correlation between nocturna
A phase 2 trial reports notable pCR rates and manageable toxicity for Disitamab Vedotin plus gemcitabine in HER2-positive MIBC patients.
A living network meta-analysis refines treatment strategies for mHSPC subgroups, favoring triplet therapy in synchronous high-volume cases and ARPI doublet therapy in others.
Long-term data show RAPID MRI-directed pathway safely avoids unnecessary biopsies while maintaining low rates of clinically significant prostate cancer.
This study identifies key germline variants and demonstrates how combining genetic data with family history improves personalized prostate cancer risk assessment in men of African ancestry, guiding future screening strategies.
Network meta-analysis suggests physical therapies may outperform drugs in managing urinary incontinence in women over 60, but certainty is low.
The FDA approved once‑daily niraparib plus abiraterone acetate and prednisone for adults with deleterious or suspected deleterious BRCA2‑mutated metastatic castration‑sensitive prostate cancer (CSPC), based on rPFS and interim overall survi
In a phase II single-arm study, BL-B01D1 demonstrated a 44.1% confirmed ORR and median PFS of 7.3 months at 2.2 mg/kg in patients with advanced urothelial carcinoma after prior systemic therapy, with predictable hematologic toxicity.
A large registry study found that men with prostate cancer who traveled ≥30 minutes to their treating facility had modestly lower all-cause and prostate cancer–specific mortality than those traveling <30 minutes, raising questions about
The NCI convened experts to provide clinical-trial design recommendations for biochemically recurrent prostate cancer in the era of PSMA PET, defining PSMA+BCR, high-risk criteria, imaging and data standards, endpoint suggestions, and a pus
In the randomized phase II LUNAR trial, adding two cycles of neoadjuvant 177Lu-PNT2002 to stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer significantly prolonged progression-free survival (17.6 vs
SunRISe-4 reports higher pCR, pOR, and 1‑year RFS for neoadjuvant TAR‑200 plus cetrelimab versus cetrelimab alone in cisplatin‑ineligible/refusing MIBC, with urinary and circulating tumor DNA MRD correlating with outcomes.
An individual-patient data meta-analysis of 10,266 men shows nonlinear oncologic benefit from longer ADT with radiotherapy (diminishing beyond 9–12 months) but increasing other-cause mortality with long-term ADT; optimal duration should be
The MAST phase III trial found no benefit of metformin (850 mg twice daily) versus placebo for delaying progression in men with low‑risk prostate cancer on active surveillance; a prespecified subgroup showed increased pathologic progression
A randomized phase III trial (MAST) found metformin did not prolong progression‑free survival in men on active surveillance for low‑risk prostate cancer; an exploratory subgroup showed increased pathologic progression in obese patients.
Comprehensive review of metformin’s role in metastatic prostate cancer with ADT highlights STAMPEDE trial’s findings: no significant overall survival benefit but metabolic side-effect mitigation. Integration of other RCTs outlin
In the PRIME randomized phase 3 trial, metformin did not significantly reduce metabolic syndrome incidence in men starting androgen deprivation therapy, but produced modest, clinically relevant reductions in body weight, waist circumference
Open language-specific specialty feeds and department pages.